Detection of Amplified Her2/Neu Gene Score 2 Cases in Breast Cancer Using Chromogenic In Situ Hybridization Al-Mugdadi Suhad Faisal Hatem1,*, Mohammed Ahmed Salahuddin2, Salman Ahmed E.1, Alsayyid Maha Mahamommed2, Naser Mustafa Mageed2 1Department of Clinical Laboratories Sciences, College of Pharmacy, Mustansiriyah University, Iraq 2Teaching Oncology Hospital, Medical City, Iraq *Corresponding author: Suhad Faisal Hatem Al-Mugdadi, E-mail: suhadhatim@uomustansiriyah.edu.iq
Online published on 4 June, 2019. Abstract Both Her2 gene and Her2 protien are part of normal cell growth they seen in the breast cells of people without cancer, but sometime mistakes in a cell DNA and mutation cause the body to create many HER2 proteins. For diagnosis of HER-2/neu gene amplification, A total of 60 paraffin embedded breast tumors block from women with final histopathology diagnosis of invasive ductal breast carcinoma. All these samples were chosen as scored 2+ (equivocal) Her-2/neu by using Immunohistochemistry (IHC) technique. CISH as molecular method to detect Her-2/neu gene amplification was used. The high number and percentage (33/55%) of the breast cancer cases were found in pre-menopause Group < 50 years old. The highest number of the breast cancer cases grade ll was must common (42/70%). There were significant differences between age groups and between all histological grades. Stage IIIA was the highest one (25/41.7%) with significant differences between all stages. Using chromogenic in situ hybridization methods to detect HER2/neu gene the amplified cases were (36.6%). There were high significant differences between age, tumor grade and stage within amplified cases. CISH is hopeful to detect gene expression when the HER2/neu is score 2 (equivocal). It is valuable and considerable when correlated its results with the age, tumor grade and stage. Top Keywords HER2/neu gene, Cancer, In Situ hybridization. Top |